Ilika updates on trading, Stereax manufacturing, and Goliath product development

Ilika Plc

Ilika plc (LON:IKA), an independent global expert in solid-state battery technology, has provided updates on trading, Stereax® manufacturing, and Goliath product development, as well as notice of its full year results for the year ended 30 April 2024.

Trading Update for FY24

Unaudited trading for the year ended 30 April 2024 has been in line with management expectations. The Company expects to announce revenues of approximately £2.1m (2023: £0.7m), and an EBITDA loss excluding share-based payments of around £4.5m (2023: EBITDA loss of £7m). Cash and cash equivalents at the period end were £11.9m (30 April 2023: £15.8m).

Operational Update

During the Period, significant progress was made with transferring manufacturing to Cirtec Medical LLC under the licence of Ilika’s thin-film Stereax miniature solid-state batteries for powering medical devices and industrial wireless sensors in specialist environments.

In addition, the Company achieved significant milestones in developing its large-format Goliath cells for electric vehicles and cordless appliances. Recently the Company also announced that Agratas, a Tata Group global battery business, has joined its SiSTEM grant funded scale up activity.

In parallel to joining the SiSTEM project, Ilika and Agratas have entered into a 12-month agreement that will facilitate interactions between the companies to support Ilika’s journey to its D8 (50Ah, chemistry frozen) development milestone in H1 2025 – which will underpin licencing opportunities, alongside exploring wider collaboration opportunities between the two parties.

On 10 May 2024, Ilika also announced a capital raising activity comprising of a conditional placing of new ordinary shares, raising gross proceeds of £1.7m, and an open offer for new ordinary shares, with the intention to raise up to an additional £1.7m, to provide additional support for the development of its Goliath solid-state battery.

Notice of Results

The Company expects to announce its audited full year results for the year ended 30 April 2024 on Thursday 11 July 2024. 

Analyst Briefing

The management team will be hosting an in-person analyst briefing on the day, Thursday 11 July 2024, at 9.30am. Analysts who wish to attend should contact Nick Rome at Walbrook PR on +44(0)20 7933 8780 or email ilika@walbrookpr.com to register.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika moves into commercial phase with first Stereax electrode order

Ilika has received its first commercial order for Stereax battery electrodes, marking the start of scaled production for medical device applications.

Ilika plc: First Commercial Revenues Signal Pivotal Shift in Solid-State Battery Journey (Video)

Ilika plc has crossed a commercial milestone with its first regular revenue stream from its Stereax battery line, according to Dr Tom McColm of Morphose Capital. With strong cash reserves, momentum on its Goliath platform, and growing interest from defence sectors, the next 12 months could be transformational.

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

Ilika CEO Graeme Purdy shares how the company has shifted from commissioning to customer deliveries of its Stereax batteries — and why its Goliath EV programme is designed to beat the commoditised market with faster charging and extended range.

Ilika reports on-track progress across Stereax and Goliath in H1 2025/26

Ilika reports unaudited half-year results to 31 October 2025, highlighting on-schedule delivery of key commercial milestones across its Stereax medical battery and Goliath EV battery programmes, alongside continued customer validation, pilot-line commissioning, and £4.2m fundraising to support its roadmap.

Ilika secures first commercial Stereax electrode order from Cirtec Medical

Ilika has received its first revenue-generating purchase order from Cirtec Medical for the supply of Stereax electrodes, marking the transition of their partnership into commercial production.

Solid state design drives weight, cost and efficiency gains

Solid state design offers Ilika a compelling path to value through weight savings, pack simplification and improved EV performance.

Search

Search